Adamopoulou K, Gkamprana AM, Patsouras K, Halkia E. Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach. World J Hepatol 2021; 13(9): 1122-1131 [PMID: 34630879 DOI: 10.4254/wjh.v13.i9.1122]
Corresponding Author of This Article
Evgenia Halkia, MD, MSc, Consultant Physician-Scientist, Surgical Oncologist, Department of Obstetrics and Gynecology, Tzaneio General Hospital, Zanni and Afentouli 1, Pireaus 18536, Greece. evgeniahalkia@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Sep 27, 2021; 13(9): 1122-1131 Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1122
Addressing hepatic metastases in ovarian cancer: Recent advances in treatment algorithms and the need for a multidisciplinary approach
Konstantina Adamopoulou, Athanasia M Gkamprana, Konstantinos Patsouras, Evgenia Halkia
Konstantina Adamopoulou, Athanasia M Gkamprana, Konstantinos Patsouras, Evgenia Halkia, Department of Obstetrics and Gynecology, Tzaneio General Hospital, Pireaus 18536, Greece
Author contributions: Halkia E initially conceived of and designed the study and provided coordination and supervision throughout the project; Adamopoulou K and Gkamprana AM performed the literature review, data collection and prioritization, and drafted the manuscript; Halkia E and Patsouras K revised the manuscript for scientific content; Spelling and grammatical corrections were made by Halkia E; Adamopoulou K and Gkamprana AM contributed equally and share first authorship; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors report that they have no conflicting interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Evgenia Halkia, MD, MSc, Consultant Physician-Scientist, Surgical Oncologist, Department of Obstetrics and Gynecology, Tzaneio General Hospital, Zanni and Afentouli 1, Pireaus 18536, Greece. evgeniahalkia@gmail.com
Received: April 8, 2021 Peer-review started: April 8, 2021 First decision: July 8, 2021 Revised: July 21, 2021 Accepted: August 11, 2021 Article in press: August 11, 2021 Published online: September 27, 2021 Processing time: 166 Days and 20.8 Hours
Abstract
The lifetime risk for ovarian cancer incidence is 1.39% and the lifetime risk of death is 1.04%. Most ovarian cancer patients are diagnosed at advanced stages (III, IV) because there were no specific symptoms or existing screening tests. Liver metastases have been found in up to 50% of patients dying of advanced ovarian cancer. Recent studies indicate the need for a multidisciplinary approach from initial diagnosis to oncologic surgery and chemotherapy treatment, mandating the involvement of gynecologic oncologists, surgical oncologist, medical oncologists, hepatobiliary surgeons, and interventional radiologists.
Core Tip: Each year more than 295000 women are diagnosed with and 185000 die from ovarian cancer, which remains the most lethal of all gynecologic malignancies worldwide. The management of advanced ovarian cancer has evolved over the past two decades. Surgical excision and with different minimally invasive techniques are available options for treating hepatic metastasis. A multidisciplinary approach is essential to achieve optimal treatment outcomes.
